Lopinavir cerebrospinal fluid steady-state trough concentrations in HIV-infected adults

Annals of Pharmacotherapy

Volumn 43, Issue 12, 2009, Pages 1972-1977

  DiCenzo, Robert ^a,b   DiFrancesco, Robin ^c   Cruttenden, Kim ^b   Donnelly, Julie ^c   Schifitto, Giovanni ^b  

^a ST JOHN FISHER COLLEGE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Cerebrospinal fluid; HIV; Lopinavir; Pharmacokinetics; Trough concentration

Indexed keywords

ABACAVIR; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CAPSULE; FEMALE; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; LINEAR REGRESSION ANALYSIS; MALE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN CEREBROSPINAL FLUID LEVEL; STEADY STATE; WILD TYPE;

ADULT; AREA UNDER CURVE; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; LINEAR MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINONES; RITONAVIR; TIME FACTORS; VIRUS REPLICATION;

EID: 72249110851     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M399     Document Type: Article

References (19)

1. Gimenez F, Fernandez C, Mabondzo A. Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins. J Acquir Immune Defic Syndr 2004;36:649-658 (Pubitemid 38685958)
2. Wynn HE, Brundage RC, Fletcher CV. Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 2002;16:595-609. (Pubitemid 34941127)
3. Frerichs VA, DiFrancesco R, Morse GD. Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry. J Chromatogr 2003;787:393-403. (Pubitemid 36316018)
4. DiFrancesco R, DiCenzo R, Vicente G, et al. Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry. J Pharm Biomed Anal 2007;44:1139-1146 (Pubitemid 47239308)
5. Parkin NT, Hellmann NS, Whitcomb JM, et al. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48:437-443 (Pubitemid 38141699)
6. Prescribing information. Kaletra (lopinavir). North Chicago, IL: Abbott Laboratories, January 2007.
7. Zhou XJ, Havlir DV, Richman DD, et al. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. AIDS 2000;14:2869-2876
8. Burger DM, Kraaijeveld CL, Meenhorst PL, et al. Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS 1993;7:1581-1587 (Pubitemid 24008850)
9. Haworth SJ, Christofalo B, Anderson RD, et al. A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:235-238 (Pubitemid 28103590)
10. Van Praag RM, Weverling GJ, Portegies P, et al. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 2000;14:1187-1194 (Pubitemid 30420662)
11. McDowell JA, Chittick GE, Ravitch JR, et al. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob Agents Chemother 1999;43:2855-2861
12. Capparelli EV, Letendre S, Ellis R, et al. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob Agents Chemother 2004;49:2504-2506
13. Van Praag RM, van Weert EC, van Heeswijk RP, et al. Stable concentration of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy. Antimicrob Agents Chemother 2002;46:896-899
14. Letendre SL, Capparelli EV, Ellis RJ, et al. Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. Antimicrob Agents Chemother 2000;44:2173-2175 (Pubitemid 30484445)
15. Capparelli EV, Holland D, Okamoto C, et al. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS 2005;19:949-952 (Pubitemid 40834938)
16. Yeh RF, Letendre S, Novak IS, et al. Single agent therapy with lopinavir/ ritonavir controls HIV-1 replication in the central nervous system (abstract 381). Presented at: 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007.
17. Haas DW, Stone J, Clough LA, et al. Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection. Clin Pharmcol Ther 2000;68:367-374 (Pubitemid 30803525)
18. Haas DW, Johnson B, Nicotera J, et al. Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma. Antimicrob Agents Chemother 2003;47:2131-2137 (Pubitemid 36753562)
19. Fromm M. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drug. Int J Clin Pharmacol Ther 2000;38:69-74. (Pubitemid 30077981)